Show simple item record

AuthorVranic, Semir
AuthorPalazzo, Juan
AuthorSanati, Souzan
AuthorFlorento, Elena
AuthorContreras, Elma
AuthorXiu, Joanne
AuthorSwensen, Jeffrey
AuthorGatalica, Zoran
Available date2019-03-28T10:52:25Z
Publication Date2018-09-01
Publication NameClinical Breast Canceren_US
Identifierhttp://dx.doi.org/10.1016/j.clbc.2018.09.001
CitationSemirVranic el al. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.Clinical Breast Cancer . 2019. Vol. 19 , No 2
ISSN1526-8209
URIhttp://hdl.handle.net/10576/11461
AbstractNeuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific biomarkers were recently investigated in the NEC of lung and in other types of breast carcinoma, which may provide guidance to their feasibility in breast NEC. Twenty breast NECs were profiled for biomarkers of therapy including antibody-drug conjugates (DLL3, TROP-2, and FOLR1), histone deacetylase (H3K36Me3) inhibitors, tropomyosin receptor kinases (NTRK1/2/3 gene fusions) targeted inhibitors, alkylating agents (MGMT), and immune checkpoint inhibitors (PD-L1, TMB, and MSI) using immunohistochemistry and DNA/RNA next-generation sequencing assays. Predictive expression of TROP-2, FOLR1, and H3K36Me3 were detected in different subsets of tumors and may pave the way for development of novel targeted therapies in some patients with breast NECs. There was no evidence of DLL3 expression, NTRK gene fusions, or MGMT hypermethylation. No biomarkers predictive of immune checkpoint inhibitor efficacy (programmed death-ligand 1 expression, tumor mutational burden, microsatellite instability) were identified. FGFR and CCND1 gene amplifications were detected in isolated cases. This study identified several potential targets for novel therapies in breast NEC, including farletuzumab and mirvetuximab soravtansine (FOLR1), sacituzumab govitecan (TROP-2), and HDAC inhibitors (H3K36Me3). In some cases, CCND1 gene amplification may indicate the usefulness of investigational therapies. The reported results should serve as an early indication of potential clinical relevance in selected patients with breast NEC.
Languageen
PublisherElsevier
SubjectBiomarkers
SubjectBreast cancer
SubjectMolecular profiling
SubjectSpecial types
SubjectTargeted therapy
TitlePotential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
TypeArticle
Pagination131-136
Issue Number2
Volume Number19
dc.identifier.essn 1938-0666


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record